WGU D345 PSYCHOPHARMACOLOGY
FOR ADVANCED PSYCHIATRIC MENTAL
HEALTH PRACTICE – POST-MASTER'S
CERTIFICATE NURSING PMHNP STUDY
GUIDE, ORIGINAL PRACTICE
QUESTIONS & ANSWERS, D345
ASSESSMENT PREPARATION,
COMPREHENSIVE
PSYCHOPHARMACOLOGY REVIEW,
PSYCHIATRIC MED QUESTIONS AND
CORRECT ANSWERS (VERIFIED
ANSWERS) PLUS RATIONALES 2026 Q&A
| INSTANT DOWNLOAD PDF.
CORE DOMAINS
• Neurobiology and Pharmacokinetic Principles
• Mood Stabilizers and Antiepileptic Drugs
• Antipsychotic Medications
• Antidepressant Medications
• Anxiolytics and Hypnotics
• Medications for ADHD and Cognitive Disorders
, • Substance Use Disorder Pharmacotherapy
• Pharmacogenomics and Precision Psychiatry
• Regulatory, Legal, and Ethical Prescribing Standards
• Special Populations and Lifespan Considerations
INTRODUCTION
The WGU D345 Psychopharmacology for Advanced Psychiatric Mental Health
Practice assessment evaluates the PMHNP student's mastery of advanced
psychopharmacological principles essential for safe, evidence-based
prescribing. This comprehensive examination assesses knowledge of
neurobiology, drug mechanisms, therapeutic applications, adverse effect
profiles, and monitoring parameters across psychiatric disorders. The test
employs multiple-choice and scenario-based questions emphasizing clinical
decision-making, risk assessment, and patient-centered care. It rigorously
evaluates the ability to integrate pharmacogenomic data, manage complex
medication regimens, and adhere to legal and ethical prescribing standards,
ensuring readiness for autonomous psychiatric mental health nurse
practitioner practice.
SECTION ONE: QUESTIONS 1–100
1. A PMHNP is reviewing the pharmacokinetic profile of a newly
prescribed antidepressant. Which of the following processes describes
the biotransformation of the drug into metabolites?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
C. Metabolism
, RATIONALE: Metabolism, also known as biotransformation, is the
process by which the body chemically alters a drug, primarily in the liver, to
produce metabolites that are more water-soluble for excretion. Absorption
(A) is the movement of the drug into the bloodstream. Distribution (B) is the
movement of the drug to tissues. Excretion (D) is the removal of the drug
from the body.
2. A PMHNP is evaluating a patient who reports no therapeutic benefit
from sertraline despite adherence. Pharmacogenomic testing reveals
the patient is a CYP2D6 poor metabolizer. Which of the following
actions should the PMHNP take?
A. Increase the dose of sertraline.
B. Switch to a medication not metabolized by CYP2D6.
C. Add a CYP2D6 inducer to the regimen.
D. Continue the current dose and monitor for delayed response.
B. Switch to a medication not metabolized by CYP2D6.
RATIONALE: CYP2D6 poor metabolizers have reduced enzyme activity,
leading to increased plasma concentrations of drugs metabolized by this
pathway, which can cause adverse effects without necessarily improving
efficacy. Sertraline is metabolized by multiple CYP enzymes including
CYP2D6. The PMHNP should consider switching to a medication that is less
dependent on CYP2D6 metabolism. Increasing the dose (A) would exacerbate
potential toxicity.
3. A PMHNP is prescribing lithium for a patient with bipolar I disorder.
Which of the following laboratory parameters should be monitored
most closely during the initiation phase?
A. Serum sodium and potassium levels
B. Serum lithium levels, renal function, and thyroid function
, C. Complete blood count with differential
D. Liver function tests and lipid panel
B. Serum lithium levels, renal function, and thyroid function
RATIONALE: Lithium has a narrow therapeutic index and is primarily
excreted by the kidneys. Monitoring serum lithium levels, renal function
(BUN, creatinine), and thyroid function is essential during initiation and
ongoing therapy to prevent toxicity and detect adverse effects such as
nephrogenic diabetes insipidus and hypothyroidism.
4. A patient with bipolar disorder is being transitioned from lithium to
lamotrigine. Which of the following adverse effects should the PMHNP
warn the patient about?
A. Weight gain
B. Sedation
C. Serious skin rash
D. Hypertension
C. Serious skin rash
RATIONALE: Lamotrigine carries a black box warning for serious skin
reactions, including Stevens-Johnson syndrome and toxic epidermal
necrolysis. Patients should be instructed to report any rash immediately. The
medication should be titrated slowly to minimize this risk.
5. A PMHNP is initiating valproate for a patient with bipolar mania.
Which of the following laboratory tests should be obtained before
starting therapy?
A. Serum lithium level
B. Liver function tests and pregnancy test
FOR ADVANCED PSYCHIATRIC MENTAL
HEALTH PRACTICE – POST-MASTER'S
CERTIFICATE NURSING PMHNP STUDY
GUIDE, ORIGINAL PRACTICE
QUESTIONS & ANSWERS, D345
ASSESSMENT PREPARATION,
COMPREHENSIVE
PSYCHOPHARMACOLOGY REVIEW,
PSYCHIATRIC MED QUESTIONS AND
CORRECT ANSWERS (VERIFIED
ANSWERS) PLUS RATIONALES 2026 Q&A
| INSTANT DOWNLOAD PDF.
CORE DOMAINS
• Neurobiology and Pharmacokinetic Principles
• Mood Stabilizers and Antiepileptic Drugs
• Antipsychotic Medications
• Antidepressant Medications
• Anxiolytics and Hypnotics
• Medications for ADHD and Cognitive Disorders
, • Substance Use Disorder Pharmacotherapy
• Pharmacogenomics and Precision Psychiatry
• Regulatory, Legal, and Ethical Prescribing Standards
• Special Populations and Lifespan Considerations
INTRODUCTION
The WGU D345 Psychopharmacology for Advanced Psychiatric Mental Health
Practice assessment evaluates the PMHNP student's mastery of advanced
psychopharmacological principles essential for safe, evidence-based
prescribing. This comprehensive examination assesses knowledge of
neurobiology, drug mechanisms, therapeutic applications, adverse effect
profiles, and monitoring parameters across psychiatric disorders. The test
employs multiple-choice and scenario-based questions emphasizing clinical
decision-making, risk assessment, and patient-centered care. It rigorously
evaluates the ability to integrate pharmacogenomic data, manage complex
medication regimens, and adhere to legal and ethical prescribing standards,
ensuring readiness for autonomous psychiatric mental health nurse
practitioner practice.
SECTION ONE: QUESTIONS 1–100
1. A PMHNP is reviewing the pharmacokinetic profile of a newly
prescribed antidepressant. Which of the following processes describes
the biotransformation of the drug into metabolites?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
C. Metabolism
, RATIONALE: Metabolism, also known as biotransformation, is the
process by which the body chemically alters a drug, primarily in the liver, to
produce metabolites that are more water-soluble for excretion. Absorption
(A) is the movement of the drug into the bloodstream. Distribution (B) is the
movement of the drug to tissues. Excretion (D) is the removal of the drug
from the body.
2. A PMHNP is evaluating a patient who reports no therapeutic benefit
from sertraline despite adherence. Pharmacogenomic testing reveals
the patient is a CYP2D6 poor metabolizer. Which of the following
actions should the PMHNP take?
A. Increase the dose of sertraline.
B. Switch to a medication not metabolized by CYP2D6.
C. Add a CYP2D6 inducer to the regimen.
D. Continue the current dose and monitor for delayed response.
B. Switch to a medication not metabolized by CYP2D6.
RATIONALE: CYP2D6 poor metabolizers have reduced enzyme activity,
leading to increased plasma concentrations of drugs metabolized by this
pathway, which can cause adverse effects without necessarily improving
efficacy. Sertraline is metabolized by multiple CYP enzymes including
CYP2D6. The PMHNP should consider switching to a medication that is less
dependent on CYP2D6 metabolism. Increasing the dose (A) would exacerbate
potential toxicity.
3. A PMHNP is prescribing lithium for a patient with bipolar I disorder.
Which of the following laboratory parameters should be monitored
most closely during the initiation phase?
A. Serum sodium and potassium levels
B. Serum lithium levels, renal function, and thyroid function
, C. Complete blood count with differential
D. Liver function tests and lipid panel
B. Serum lithium levels, renal function, and thyroid function
RATIONALE: Lithium has a narrow therapeutic index and is primarily
excreted by the kidneys. Monitoring serum lithium levels, renal function
(BUN, creatinine), and thyroid function is essential during initiation and
ongoing therapy to prevent toxicity and detect adverse effects such as
nephrogenic diabetes insipidus and hypothyroidism.
4. A patient with bipolar disorder is being transitioned from lithium to
lamotrigine. Which of the following adverse effects should the PMHNP
warn the patient about?
A. Weight gain
B. Sedation
C. Serious skin rash
D. Hypertension
C. Serious skin rash
RATIONALE: Lamotrigine carries a black box warning for serious skin
reactions, including Stevens-Johnson syndrome and toxic epidermal
necrolysis. Patients should be instructed to report any rash immediately. The
medication should be titrated slowly to minimize this risk.
5. A PMHNP is initiating valproate for a patient with bipolar mania.
Which of the following laboratory tests should be obtained before
starting therapy?
A. Serum lithium level
B. Liver function tests and pregnancy test
